GHRP-6 Reference

Educational, not medical advice reference for GHRP-6: GH Release; regulatory status, evidence posture, source review, and schedule notes. Also k…

Plain English

What it is
GHRP-6 is a lab-made peptide, which is a short chain of amino acids. It mimics ghrelin, the body's hunger hormone, by switching on the same receptor, which tells the brain to release a pulse of natural growth hormone. It is sold only as a research chemical and is not an FDA-approved medicine.
What people use it for
In the peptide community, people use it to push the body to put out more of its own growth hormone. Its standout feature is a strong, reliable boost in appetite, so it is popular with people who are trying to eat more and build muscle.
What the science shows
Older short-term studies in healthy men showed that it does trigger growth hormone release, and that it works together with another hormone called GHRH to release even more. Animal studies show it strongly switches on the brain's appetite centers. The human research is dated and limited, with little long-term safety or outcome data, and nothing like the modern testing done for newer peptides.
The catch
It is not an approved drug, and the FDA has flagged GHRP-6 as a bulk substance that may pose safety risks when used in pharmacy compounding. It is also banned in sport at all times under World Anti-Doping Agency rules. The appetite effect can be intense, and the long-term effects in people are not well understood.

Reference summary

Early human GH-response work in healthy volunteers documented GH secretion following GHRP-6 administration. Evidence is older and primarily short-term; long-term clinical outcome data are limited, and no modern PK/PD or outcome program comparable to ipamorelin or CJC-1295 exists.

Regulatory and posture

Categories
GH Release
Aliases
SKF-110679, Growth hormone releasing hexapeptide
Evidence posture
translational - Evidence is limited to older, short-term human GH-response studies without modern PK/PD or outcome follow-up. Strong ghrelin-class appetite stimulation is consistently reported.
Regulatory status
No FDA-approved GHRP-6 drug label. FDA lists GHRP-6 among bulk drug substances with safety-risk concerns for compounding.
Content review status
research reference

Selected public sources

Related tools

For research and educational purposes only. Not medical advice.